Monoclonal Antibody Therapy in Treating Patients With Refractory Advanced Solid Tumors or Lymphoma

Completed · Phase 1

Conditions studied: Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific

In brief

RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody therapy in treating patients who have refractory advanced solid tumors or lymphoma.

Key facts

Study ID

NCT00049712

Run by

University of Wisconsin, Madison

Starts

2002-10-01

Expected to finish

2006-02-01

Last updated by the study team

2019-12-13

Who can join

Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Wisconsin Comprehensive Cancer Center — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.